Kymera Therapeutics (Kymera Therapeutics (KYMR)) shares jumped more than 20% on Thursday after the company announced it had completed enrollment in its BROADEN2 Phase 2b trial for KT-621, a treatment for moderate to severe atopic dermatitis — the most common form of eczema. The milestone came nearly six months ahead of schedule, which means patients and investors won't have to wait as long for results.
The news landed on a strong day for markets, with the S&P 500 up 0.3% and the healthcare sector gaining 2.2%. Kymera's stock was up about 16% at $115.65 by publication time, after hitting a new 52-week high earlier in the session.
Why the Early Finish Matters
Completing enrollment early isn't just a nice-to-have — it compresses the entire development timeline. Kymera now expects topline data from the BROADEN2 trial by the end of 2026, and the company plans to kick off Phase 3 trials by mid-2027. That's a meaningful acceleration for a drug that could become a blockbuster in the eczema market.
“With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent readouts, and NDA filing,” said Nello Mainolfi, Founder, President, and CEO of Kymera Therapeutics.
Technical Check: Momentum Is Strong, But Watch for Pullback
Kymera's stock is trading at $121.03, well above its 20-day simple moving average of $85.20 — a classic sign of bullish momentum. But the Relative Strength Index (RSI) sits at 84.74, which is firmly in overbought territory. That doesn't mean the stock will drop tomorrow, but it suggests the rally might be getting a little frothy.
Key resistance is at $125.00, a level that aligns with recent swing highs. On the downside, $90.00 is the key support level to watch, near the 20-day exponential moving average.
How Kymera Stacks Up Against the Market
According to market data, Kymera's momentum score is a bullish 91.55, meaning the stock is outperforming the broader market by a wide margin. The signal points to a strong momentum-driven story, with the stock performing well compared to its peers in the healthcare sector.
ETF Exposure: Where to Find Kymera in Funds
For investors who prefer ETFs, Kymera has notable weightings in a couple of funds. The ALPS Medical Breakthroughs ETF (ALPS Medical Breakthroughs ETF (SBIO)) holds a 4.16% weight in the stock, while the Harbor Human Capital Factor US Small Cap ETF (Harbor Human Capital Factor US Small Cap ETF (HAPS)) has a 1.82% weight.
Kymera's stock is up more than 15% on the day, and with a clear path forward for KT-621, the story is far from over. But as with any biotech rally, investors should keep an eye on those overbought signals — and the data readout later this year.
